622 completed, 157 terminated, 111 recruiting, 69 unknown. 1077 Phase 3, 221 Phase 2.
Follow Neurodegenerative Diseases: new trials by email Literature Review of Neurodegenerative Diseases trials Research Report on Neurodegenerative Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD) GV1001 Placebo, GV1001 1.12mg - Moderate to Severe Alzheimer's Disease | Phase 3 | Not yet recruiting | Samsung Pharmaceutical Co., Ltd. | 750 | 2027-07-01 | 2026-06-10 |
| Tricaprilin Phase 3 ALTER-AD (Alternative-Alzheimer Disease) Study Tricaprilin, Placebo - Alzheimer Disease | Phase 3 | Not yet recruiting | Cerecin | 535 | 2027-07-01 | 2026-10-30 |
| A Trial of ONO-2808 in Participants With the Parkinsonian Subtype of Multiple System Atrophy (MSA-P) ONO-2808, Placebo - Multiple System Atrophy, Parkinson Variant | Phase 3 | Not yet recruiting | Ono Pharmaceutical Co., Ltd. | 486 | 2027-01-01 | 2026-09-17 |
| A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Trontinemab, Placebo - Alzheimer's Disease | Phase 3 | Recruiting | Hoffmann-La Roche | 1600 | 2026-11-30 | 2026-10-13 |
| Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 PLX-200, Placebo - Juvenile Neuronal Ceroid Lipofuscinosis | Phase 3 | Withdrawn | Polaryx Therapeutics, Inc. | 2026-11-01 | 2026-08-19 | |
| To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE) Acoramidis (AG10) - Amyloidosis in Transthyretin (TTR), Amyloidosis, Familial | Phase 3 | Not yet recruiting | Eidos Therapeutics, a BridgeBio company | 250 | 2026-11-01 | 2026-08-11 |
| A Study to Learn About the Safety and Effects of Salanersen (BIIB115) When Given to Babies With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec Salanersen, Sham Procedure - Muscular Atrophy, Spinal | Phase 3 | Recruiting | Biogen | 42 | 2026-10-31 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia Nomlabofusp, Placebo - Friedreich Ataxia, Friedreich's Ataxia | Phase 3 | Recruiting | Larimar Therapeutics, Inc. | 150 | 2026-10-26 | 2026-10-09 |
| A Phase 2b/3 Clinical Study Evaluating T3D-959 in Mild-to-Moderate Alzheimer's Disease Subjects T3D-959, Placebo Comparator - Alzheimer's Disease | Phase 2 / Phase 3 | Not yet recruiting | T3D Therapeutics, Inc. | 376 | 2026-10-26 | 2025-05-09 |
| Effect of Botulinum Toxin on Resting Tremor of the Refractory Upper Limb in Parkinsonians Injection of Dysport then placebo, Injection of placebo then Dysport - PARKINSON DISEASE (Disorder) | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 39 | 2026-10-01 | 2026-09-22 |
| Efficacy and Safety of Tazbentetol in ALS Participants Tazbentetol, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Not yet recruiting | Spinogenix | 430 | 2026-10-01 | 2026-09-10 |
| An Open-label Long-term Safety Study of Buntanetap in Participants With AD buntanetap/posiphen - Alzheimer's Dementia (AD) | Phase 2 / Phase 3 | Not yet recruiting | Annovis Bio Inc. | 400 | 2026-09-21 | 2026-08-19 |
| An Open Label Individual Patient (OLIP)-02 Study of Nusinersen (BIIB058) Nusinersen Injectable Product - SMA - Spinal Muscular Atrophy | Phase 3 | Not yet recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 | 2026-09-17 | 2026-09-29 |
| A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis Rozanolixizumab - Ocular Myasthenia Gravis | Phase 3 | Recruiting | UCB Biopharma SRL | 100 | 2026-09-16 | 2026-10-27 |
| A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam Salanersen - Spinal Muscular Atrophy | Phase 3 | Recruiting | Biogen | 90 | 2026-09-08 | 2026-10-02 |
| Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. TETA 4HCl formulation, D-Penicillamine - Wilson's Disease | Phase 3 | Recruiting | Orphalan | 38 | 2026-09-03 | 2026-10-15 |
| A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping AOC 1044, Placebo - Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) | Phase 3 | Recruiting | Avidity Biosciences, Inc. | 70 | 2026-09-01 | 2026-10-13 |
| Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy 3-N-butylphthalide - Multiple System Atrophy | Phase 2 / Phase 3 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 150 | 2026-08-27 | 2026-10-16 |
| Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION) Everolimus, Tacrolimus or Cyclosporine - Liver Allograft, Liver Diseases | Phase 3 | Recruiting | Hannover Medical School | 150 | 2026-08-19 | 2026-10-05 |
| Pivotal Study of N-acetyl-L-leucine for CACNA1A N-Acetyl-L-Leucine, Placebo - CACNA1A, Spinocerebellar Ataxia Type 6 | Phase 3 | Recruiting | IntraBio Inc | 60 | 2026-08-17 | 2026-09-08 |
Showing 20 of 1077. Sign in to see all of them.
Alzheimer Disease (346) · Parkinson Disease (289) · Dementia (110) · Amyotrophic Lateral Sclerosis (90) · Myasthenia Gravis (79) · Cognitive Dysfunction (46) · Huntington Disease (29) · Nervous System Diseases (28) · Brain Diseases (26) · Muscular Atrophy, Spinal (26) · Psychomotor Agitation (26) · Dyskinesias (24) · Amyloid Neuropathies, Familial (22) · Mental Disorders (22)
Nervous System Diseases (1049) · Central Nervous System Diseases (880) · Brain Diseases (738) · Mental Disorders (404) · Neurocognitive Disorders (382) · Basal Ganglia Diseases (371) · Movement Disorders (364) · Tauopathies (346) · Synucleinopathies (307) · Parkinsonian Disorders (280) · Dementia (279) · Neuromuscular Diseases (277) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (228) · Heredodegenerative Disorders, Nervous System (220)
Galantamine (20) · Donepezil (18) · Pramipexole (18) · rasagiline (18) · carbidopa, levodopa drug combination (17) · Levodopa (16) · Memantine (15) · rotigotine (15) · Riluzole (13) · Aripiprazole (11) · istradefylline (11) · Apomorphine (10) · gantenerumab (10) · latrepirdine (10) · safinamide (10)
Novartis Pharmaceuticals (24) · Hoffmann-La Roche (21) · Pfizer (21) · Eli Lilly and Company (19) · Otsuka Pharmaceutical Development & Commercialization, Inc. (17) · Alexion Pharmaceuticals, Inc. (16) · Biogen (16) · UCB Pharma (16) · Assistance Publique - Hôpitaux de Paris (13) · Boehringer Ingelheim (13) · GlaxoSmithKline (13) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (13) · UCB Biopharma SRL (13) · Teva Branded Pharmaceutical Products R&D, Inc. (11) · AbbVie (10)
United States (612) · Canada (307) · Germany (280) · Spain (274) · France (263) · United Kingdom (262) · Italy (258) · Australia (182) · Poland (181) · Japan (171) · Netherlands (147) · Belgium (133) · South Korea (114) · China (108) · Czechia (87)
PMID 39498781, PMID 40603145, PMID 39800465, PMID 26120369, PMID 26402769, PMID 30936738, PMID 33189083, PMID 34383289, PMID 36449262, PMID 40681915, PMID 41533472, PMID 41961243, PMID 27538531, PMID 28494751, PMID 29318278, PMID 30474567, PMID 31193334, PMID 34108929, PMID 34115419, PMID 36602886, PMID 36946603, PMID 37059507, PMID 37460782, PMID 38588457, PMID 39108660, PMID 39556389, PMID 41537338, PMID 41591746, PMID 42388397, PMID 42552749, PMID 42841310, PMID 19126811, PMID 20519680, PMID 20921879, PMID 21542016, PMID 21779958, PMID 22749065, PMID 23667214, PMID 24450890, PMID 24450891, PMID 25125457, PMID 25185211, PMID 25982504, PMID 26208959, PMID 26297092, PMID 26523919, PMID 26554876, PMID 26666500, PMID 26882318, PMID 27176461
2025 (22), 2023 (19), 2016 (18), 2015 (17), 2019 (17), 2018 (16), 2017 (15), 2008 (7), 2009 (7), 2014 (6), 2004 (5), U01AG010483 (5), U01AG059798 (5), R01AG046179 (4), U01AG042791 (4)